Haleon (LSE:HLN) said first-quarter organic revenue rose 2.2%, as strength in Oral Health and a return to growth in North America helped offset a weak cold and flu season.
The consumer health group reported revenue of £2.86 billion for the three months to 31 March 2026, up 0.1% on a reported basis. Organic growth was driven by a 2.4% price contribution, while volume/mix slipped 0.2%. Haleon estimated the soft cold and flu season cut around 130 basis points from quarterly growth.
North America delivered 1% organic revenue growth, despite pressure from cold and flu products, while EMEA and Latin America grew 2.1% and APAC rose 4.0%. Oral Health was the clearest bright spot, with organic revenue up 8.3%, helped by double-digit growth in Sensodyne and parodontax.
Respiratory Health declined 3.4% organically, while Pain Relief and Digestive Health were broadly flat to slightly lower. Vitamins, Minerals and Supplements grew 1.7%, supported by Centrum across regions.
Chief executive Brian McNamara said the group delivered “a competitive performance in a challenging market”, adding that innovation and geographic expansion drove double-digit growth in Sensodyne and parodontax.
Haleon reiterated its full-year outlook for 3–5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. The company also said £500 million had been allocated to share buybacks in 2026, with about 36% completed.
